Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (391-400 of 584) with videos related to

Pageof 59
Sort By:
Blood|May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndromeHesham M Amin, Iman Jilani, Elihu H Estey, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Haematologica|June 18, 2026
Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II studyCarlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, et al.
Blood|June 22, 2012
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsSrdan Verstovsek, Hagop M Kantarjian, Zeev Estrov, et al.
American Journal of Hematology|October 6, 2018
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITYRüdiger Hehlmann, Jorge E Cortes, Teresa Zyczynski, et al.
Haematologica|May 14, 2016
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisKoji Sasaki, Hagop Kantarjian, Elias Jabbour, et al.
Haematologica|July 10, 2025
Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN surveyFabian Lang, Zack Pemberton-Whiteley, Joannie Clements, et al.
American Journal of Hematology|October 10, 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsIman Abou Dalle, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndromeRazelle Kurzrock, Maher Albitar, Jorge E Cortes, et al.
Cancer|September 17, 2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AMLJorge E Cortes, Stuart L Goldberg, Eric J Feldman, et al.
Pageof 59

Showing results (391-400 of 584) with videos related to

Sort By:
Pageof 59
Blood|May 6, 2003
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndromeHesham M Amin, Iman Jilani, Elihu H Estey, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Haematologica|June 18, 2026
Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II studyCarlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, et al.
Blood|June 22, 2012
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsSrdan Verstovsek, Hagop M Kantarjian, Zeev Estrov, et al.
American Journal of Hematology|October 6, 2018
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITYRüdiger Hehlmann, Jorge E Cortes, Teresa Zyczynski, et al.
Haematologica|May 14, 2016
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisKoji Sasaki, Hagop Kantarjian, Elias Jabbour, et al.
Haematologica|July 10, 2025
Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN surveyFabian Lang, Zack Pemberton-Whiteley, Joannie Clements, et al.
American Journal of Hematology|October 10, 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsIman Abou Dalle, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndromeRazelle Kurzrock, Maher Albitar, Jorge E Cortes, et al.
Cancer|September 17, 2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AMLJorge E Cortes, Stuart L Goldberg, Eric J Feldman, et al.
Pageof 59